Use of tetrahydrocannabinol and/or cannabidiol for the treatment of inflammatory bowel disease

Roger Guy Pertwee (Inventor), Geoffrey W Guy (Inventor), Joanna Jamontt (Inventor), Philip Robson (Inventor)

Research output: Patent

Abstract

The present invention relates to the use of a substantially pure tetrahydrocannabinol (THC) or a THC containing extract in which THC is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. A further embodiment of the invention relates to the use of a substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. Additionally the substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid are used in the manufacture of a medicament for use as an adjunct therapy in the treatment of an inflammatory bowel disease.
Original languageEnglish
Patent numberWO2009004302
IPCA61K31/05; A61K31/352; A61K36/185; A61P19/08;
Publication statusPublished - 8 Jan 2009

Fingerprint

Cannabidiol
Dronabinol
Inflammatory Bowel Diseases
Cannabinoids

Cite this

Pertwee, R. G., Guy, G. W., Jamontt, J., & Robson, P. (2009). IPC No. A61K31/05; A61K31/352; A61K36/185; A61P19/08; . Use of tetrahydrocannabinol and/or cannabidiol for the treatment of inflammatory bowel disease. (Patent No. WO2009004302).

Use of tetrahydrocannabinol and/or cannabidiol for the treatment of inflammatory bowel disease. / Pertwee, Roger Guy (Inventor); Guy, Geoffrey W (Inventor); Jamontt, Joanna (Inventor); Robson, Philip (Inventor).

IPC No.: A61K31/05; A61K31/352; A61K36/185; A61P19/08; . Patent No.: WO2009004302.

Research output: Patent

Pertwee, RG, Guy, GW, Jamontt, J & Robson, P 2009, Use of tetrahydrocannabinol and/or cannabidiol for the treatment of inflammatory bowel disease, Patent No. WO2009004302, IPC No. A61K31/05; A61K31/352; A61K36/185; A61P19/08; .
Pertwee RG, Guy GW, Jamontt J, Robson P, inventors. Use of tetrahydrocannabinol and/or cannabidiol for the treatment of inflammatory bowel disease. A61K31/05; A61K31/352; A61K36/185; A61P19/08; . 2009 Jan 8.
Pertwee, Roger Guy (Inventor) ; Guy, Geoffrey W (Inventor) ; Jamontt, Joanna (Inventor) ; Robson, Philip (Inventor). / Use of tetrahydrocannabinol and/or cannabidiol for the treatment of inflammatory bowel disease. IPC No.: A61K31/05; A61K31/352; A61K36/185; A61P19/08; . Patent No.: WO2009004302.
@misc{53841a2913e24b5bbdf87f5dd9b5498e,
title = "Use of tetrahydrocannabinol and/or cannabidiol for the treatment of inflammatory bowel disease",
abstract = "The present invention relates to the use of a substantially pure tetrahydrocannabinol (THC) or a THC containing extract in which THC is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. A further embodiment of the invention relates to the use of a substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. Additionally the substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid are used in the manufacture of a medicament for use as an adjunct therapy in the treatment of an inflammatory bowel disease.",
author = "Pertwee, {Roger Guy} and Guy, {Geoffrey W} and Joanna Jamontt and Philip Robson",
year = "2009",
month = "1",
day = "8",
language = "English",
type = "Patent",
note = "WO2009004302; A61K31/05; A61K31/352; A61K36/185; A61P19/08;",

}

TY - PAT

T1 - Use of tetrahydrocannabinol and/or cannabidiol for the treatment of inflammatory bowel disease

AU - Pertwee, Roger Guy

AU - Guy, Geoffrey W

AU - Jamontt, Joanna

AU - Robson, Philip

PY - 2009/1/8

Y1 - 2009/1/8

N2 - The present invention relates to the use of a substantially pure tetrahydrocannabinol (THC) or a THC containing extract in which THC is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. A further embodiment of the invention relates to the use of a substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. Additionally the substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid are used in the manufacture of a medicament for use as an adjunct therapy in the treatment of an inflammatory bowel disease.

AB - The present invention relates to the use of a substantially pure tetrahydrocannabinol (THC) or a THC containing extract in which THC is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. A further embodiment of the invention relates to the use of a substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. Additionally the substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid are used in the manufacture of a medicament for use as an adjunct therapy in the treatment of an inflammatory bowel disease.

M3 - Patent

M1 - WO2009004302

ER -